Zenas BioPharma, Inc.
NASDAQ:ZBIOBiotechnology
+$0.64 today
- Market cap
- $1.79B
- Beta
- -0.69
- P/E (TTM)
- -2.5
- EPS (TTM)
- -$7.64
Volume 0.48M
Average 0.71M
ZBIO Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Zenas BioPharma, Inc.NASDAQ: ZBIO
Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026
Cost of revenue remains negative
Q1 FY2026 cost of revenue was $6K, compared with $0 a year earlier. Trailing-twelve-month cost of revenue was $103.75M.
Context
- Cost of revenue amounted to 0.0% of revenue in FY2025, down 2782.8 pp from a year earlier.
- Cost of revenue increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly cost of revenue holds near $6K or moves back toward the trailing-twelve-month quarterly average of $25.94M.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 0 USD
- Year-over-year change
- -100.0%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | -100.0% |
| FY2024 | 2024-12-31 | 139.14M | — |
| FY2023 | 2023-12-31 | 0 | -100.0% |
| FY2022 | 2022-12-31 | 61.69M | — |
Cost of Revenue vs competitors
How ZBIO compares with its peers on the latest reported figures
- ZBIO's LTM Mar 2026 cost of revenue of $103.75M is the 2nd highest of the 8 companies compared; the peer median is $362K.
- Its year-over-year change of +54.1% is the highest of 4, against a peer median of -8.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
TRAXFirst Tracks Biotherapeutics Inc | FY2025 | $139.61M | -8.4% | — | — |
| LTM Mar 2026 | $103.75M | +54.1% | — | — | |
| LTM Mar 2026 | $1.98M | -86.0% | -44.1% | 23.7% | |
| LTM Mar 2026 | $1.9M | — | — | — | |
| LTM Mar 2026 | $362K | +0.6% | -46.8% | 0.7% | |
| FY2025 | $234K | — | — | — | |
UPBUpstream Bio, Inc. | LTM Mar 2026 | $49K | — | — | 1.5% |
| LTM Sep 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding ZBIO) | $362K | -8.4% | -45.4% | 1.1% | |
Competitors are the stored peer set for ZBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 50M | 5M | 10M |
| Cost of Revenue | 61.69M | 0 | 139.14M | 0 |
| Gross Profit | (61.69M) | 50M | (134.14M) | 10M |
| Gross Margin | — | 100.0% | -2682.8% | 100.0% |
| Research & Development | 62.69M | 60.03M | 139.14M | 168.06M |
| Selling, General & Admin | 13.51M | 17.11M | 29.75M | 53.32M |
| Operating Expenses | 14.51M | 87.15M | 29.75M | 221.39M |
| Depreciation & Amortization | 78K | 113K | 137K | 56K |
| EBITDA | (75.12M) | (27.03M) | (156.42M) | (370.43M) |
| EBITDA Margin | — | -54.1% | -3128.4% | -3704.3% |
| Operating Income | (76.2M) | (37.15M) | (163.89M) | (211.39M) |
| Operating Margin | — | -74.3% | -3277.8% | -2113.8% |
| Interest Income | 0 | 0 | 0 | 12.15M |
| Interest Expense | 0 | 0 | 0 | 7.33M |
| Other Income / Expenses | (43.08M) | 324K | 7.33M | (166.43M) |
| Income Before Tax | (119.28M) | (36.82M) | (156.56M) | (377.82M) |
| Pre-Tax Margin | — | -73.6% | -3131.2% | -3778.2% |
| Income Tax Expense | 0 | 301K | 429K | (79K) |
| Net Income | (119.28M) | (37.12M) | (156.99M) | (377.74M) |
| Net Margin | — | -74.2% | -3139.8% | -3777.4% |
| EPS (Basic) | (3.11) | (0.97) | (3.76) | (8.44) |
| EPS (Diluted) | (3.11) | (0.97) | (3.76) | (8.44) |
| Weighted Avg Shares | 38.32M | 38.32M | 41.79M | 44.73M |
| Weighted Avg Shares (Diluted) | 38.32M | 38.32M | 41.79M | 44.73M |
Zenas BioPharma, Inc.
NASDAQ:ZBIO
Intrinsic Alpha fair value
Locked
Current Price
$26.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.